anagrelide agrylinxagrid shire thromboreductin aop orphan pharmaceuticals ag drug used treatment essential thrombocytosis also known essential thrombocythemia overproduction blood platelets also used treatment chronic myeloid anagrelide controlled release phase iii clinical trials galena biopharma treatment essential anagrelide used treat essential thrombocytosis especially current treatment patient essential thrombocytosis patients suitable anagrelide often meet one following according medical research council randomized trial combination hydroxyurea aspirin superior combination anagrelide aspirin initial management essential thrombocytosis hydroxyurea arm lower likelihood myelofibrosis arterial thrombosis bleeding slightly higher rate venous anagrelide useful times hydroxyurea proves ineffective common side effects headache diarrhea unusual weaknessfatigue hair loss nausea mrc trial mentioned also analyzed effects anagrelide bone marrow fibrosis common feature patients myelofibrosis use anagrelide associated rapid increase degree reticulin deposition mechanism fibrosis occurs compared hydroxyurea used patients myeloproliferative conditions known slow somewhat variable course marrow fibrosis increase trend may accelerated anagrelide increase fibrosis appeared linked drop hemoglobin progressed stopping anagrelide switching patients hydroxyurea appeared reverse degree marrow fibrosis thus patients anagrelide may need monitored periodic basis marrow reticulin scores especially anemia develops becomes pronounced present less common side effects include congestive heart failure myocardial infarction cardiomyopathy cardiomegaly complete heart block atrial fibrillation cerebrovascular accident pericarditis pulmonary infiltrates pulmonary fibrosis pulmonary hypertension pancreatitis gastricduodenal ulceration renal impairmentfailure seizure due issues anagrelide generally considered first line therapy essential thrombocytosis anagrelide works inhibiting maturation platelets exact mechanism action unclear although known phosphodiesterase potent inhibitor phosphodiesteraseiicitation needed inhibits phospholipase condensation benzyl chloride ethyl ester glycine gives alkylated product reduction nitro group leads aniline reaction cyanogen bromide possibly gives cyanamide initial intermediate addition aliphatic would lead formation quinazoline ring amide formation newly formed imide ester would serve form imidazolone ring whatever details sequence obtained anagrelide httpsenwikipediaorgwikianagrelide